AOD 9604 (5mg)

AOD 9604 is a modified fragment of human growth hormone, synthesized and lyophilized in the USA. The peptide is purified by multiple rounds of high-performance liquid chromatography and verified by mass spectrometry before release, with batch certificates published on our website.

AOD 9604 (5mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

Laboratory programs frequently validate AOD 9604 (5mg) with HPLC purity checks and mass confirmation before assay work begins.

AOD 9604 (5mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with AOD 9604 (5mg). Summaries are provided for orientation only and reflect the cited sources.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice^[1] — This study examined the effects of the lipolytic fragment of human growth hormone, AOD9604, and full-length human GH on lipid metabolism after chronic treatment in obese mice, including animals lacking the beta-3 adrenergic receptor. The results suggested that AOD9604 can influence body weight and fat metabolism through lipolytic pathways that may not depend entirely on beta-3-AR signaling. The findings provided early evidence supporting research interest in AOD9604 as a metabolically active hGH fragment. (Endocrinology 2001)

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone^[2] — This work characterized the metabolic profile of AOD9604, a synthetic lipolytic domain derived from human growth hormone, in animal models. The findings indicated that this fragment retains fat-mobilizing (lipolytic) activity associated with the parent hormone while representing a structurally distinct peptide. These results contributed to the foundation for studying AOD9604 as a potential regulator of lipid metabolism. (Hormone Research 2000)

Detection and in vitro metabolism of AOD9604^[3] — This study developed analytical detection methods for AOD9604 and examined its in vitro metabolism, in the context of doping-control testing. The results indicated that AOD9604 undergoes metabolism in biological samples, providing information relevant to its detection in anti-doping analysis. The work highlights AOD9604's status as a monitored peptide in sport and adds to knowledge of its metabolic stability. (Drug Testing and Analysis 2015)

References

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001. pubmed.ncbi.nlm.nih.gov/11713213/
2. Ng FM, et al.. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research. 2000. pubmed.ncbi.nlm.nih.gov/11146367/
3. Cox HD, et al.. "Detection and in vitro metabolism of AOD9604." Drug Testing and Analysis. 2015. pubmed.ncbi.nlm.nih.gov/25208511/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.